Gregory L. Weaver's most recent trade in Altimmune Inc was a trade of 259,000 Stock Options (option to buy) done . Disclosure was reported to the exchange on Feb. 26, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Altimmune Inc | Gregory L. Weaver | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 259,000 | 259,000 | - | - | Stock Options (option to buy) | |
| Altimmune Inc | Gregory L. Weaver | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2026 | 111,000 | 111,000 | - | - | Restricted Stock Units | |
| Altimmune Inc | Gregory L. Weaver | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2025 | 18,750 | 56,250 | - | - | Restricted Stock Units | |
| Altimmune Inc | Gregory L. Weaver | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2025 | 18,750 | 28,750 (0%) | 0% | 0 | Common Stock, par value $0.0001 | |
| Altimmune Inc | Gregory L. Weaver | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.28 per share. | 11 Nov 2025 | 5,672 | 23,078 (0%) | 0% | 4.3 | 24,276 | Common Stock, par value $0.0001 |
| Altimmune Inc | Gregory L. Weaver | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 166,800 | 166,800 | - | - | Stock Options (option to buy) | |
| Altimmune Inc | Gregory L. Weaver | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 57,900 | 57,900 | - | - | Restricted Stock Units | |
| Altimmune Inc | Gregory L. Weaver | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.20 per share. | 13 Mar 2025 | 10,000 | 10,000 (0%) | 0% | 5.2 | 51,996 | Common Stock, par value $0.0001 |
| Atossa Therapeutics Inc | Gregory L. Weaver | Director, EVP & CFO | Purchase of securities on an exchange or from another person at price $ 0.97 per share. | 20 Jun 2023 | 50,000 | 50,055 (0%) | 0% | 1.0 | 48,500 | Common Stock |
| Atossa Therapeutics Inc | Gregory L. Weaver | Director, EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 2,600,000 | 2,600,000 | - | - | Stock Option (right to buy) | |
| Atossa Therapeutics Inc | Gregory L. Weaver | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2022 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| ATAI Life Sciences N.V. | Gregory L. Weaver | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 228,000 | 228,000 | - | - | Stock Option | |
| ATAI Life Sciences N.V. | Gregory L. Weaver | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 22 Jun 2021 | 4,666 | 4,666 | - | 15 | 69,990 | Common Shares |
| ATAI Life Sciences N.V. | Gregory L. Weaver | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 67,726 | 67,726 | - | - | Stock Option | |
| ATAI Life Sciences N.V. | Gregory L. Weaver | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 67,726 | 67,726 | - | - | Stock Option | |
| Atossa Therapeutics Inc | Gregory L. Weaver | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 50,000 | 50,000 | - | - | Stock Option (right to buy) |